FivepHusion shared a post on LinkedIn:
“FivepHusion is excited to announce a deal with the University of Wollongong for the innovative ResectAssist™ Platform.
ResectAssist™ is a next-generation drug delivery technology that enables targeted delivery of cancer medicines directly into solid tumours via standard endoscopy, facilitating focused high dose therapy, maximising anti-cancer efficacy and minimising side effects.
The first therapy in development from the ResectAssist™ Platform is the optimised delivery of the most efficacious drugs for pancreatic cancer, which is projected to become the 2nd leading cause of cancer-related deaths by 2030 and is a US$4B global market opportunity.
ResectAssist™ is an exciting pipeline development opportunity aligned with FivepHusion’s strategy of optimising cancer therapeutics to improve patient treatment outcomes and quality of life.”
